← Back to catalogue
Research draft

Alzheimer's disease

vr.tr.alzheimer-s-disease · XCT.STA

Let an agent give accurate general information on Alzheimer's disease, recognise changes needing assessment, explain diagnosis, care and research with evidence, and point to specialist care and support for people and carers without individual medical advice.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent give accurate general information on Alzheimer's disease, recognise changes needing assessment, explain diagnosis, care and research with evidence, and point to specialist care and support for people and carers without individual medical advice.

A progressive neurodegenerative disease and the most common cause of dementia, characterised by accumulation of amyloid plaques and tau tangles in the brain, leading to memory loss, cognitive decline and changes in behaviour, usually in older age but with rarer early-onset and inherited forms; it is diagnosed by clinical assessment, imaging and biomarkers, and managed with supportive care and, increasingly, disease-modifying therapies.

What it is for: A neurodegenerative disease requiring diagnosis, care and support.

It can be explain the disease and its stages in general terms; recognise changes needing assessment; explain diagnosis, treatment and research; find specialist services and carer support.

Distinguishing features

Most common dementia

Amyloid and tau pathology

Progressive

Late and early-onset forms

What it looks like

Not physical; progressive memory and cognitive changes.

How it is recognised

Progressive memory loss and cognitive decline

Amyloid and tau pathology

Other dementias have different patterns and causes

Related models

is a kind of - category

tauopathy

is a kind of - category

aging-associated disease

is a - neurodegenerative disease

neurodegeneration

affects - organ

brain

In practice

Families and kinds

late-onset Alzheimer's disease

early-onset Alzheimer's disease

inherited autosomal dominant forms

mixed dementia with vascular changes

preclinical and prodromal stages

Standards and regulation

Clinical guidelines from neurology and dementia bodies

Medicines regulation for disease-modifying therapies

Care standards and dementia strategies

Failure modes and hazards

Missing treatable causes of cognitive change

Agents diagnosing

Unproven treatments and scams targeting people with dementia

Also called

early-onset autosomal dominant Alzheimer diseaseAlzheimer disease 16Alzheimer disease 17Alzheimer disease 18Alzheimer disease 19early-onset Alzheimer's diseaseAlzheimer disease type 1Alzheimer disease, susceptibility to, mitochondrialAlzheimer disease without neurofibrillary tanglesAlzheimer's disease 1

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Assess Changes to check.

Assessment first.

Signs

Warning changes.

Signs

Warning changes.

  1. Are there progressive memory or thinking changes that affect daily life and warrant assessment? boundary
  2. Should the person see a doctor for evaluation, including of treatable causes? action

Urgent

Urgent situations.

Urgent

Urgent situations.

  1. Is there sudden confusion, a wandering person at risk or another emergency? boundary
  2. Which service should be contacted now? action
Understand The disease.

General information.

Mechanism

What happens in the brain.

Mechanism

Mechanism.

  1. What is known about the causes and brain changes of Alzheimer's disease, according to research? provenance
  2. Is the user asking about their own diagnosis or test results? boundary

Risk

Risk and genetics.

Risk

Risk.

  1. What do health authorities say about risk factors, protective factors and inherited forms? provenance
  2. Who is eligible for genetic counselling? provenance
Care Treatment and support.

Evidence-based care.

Treatment

Care options.

Treatment

Care options.

  1. Which treatments and supportive care exist, in general terms, and what is the evidence for new disease-modifying therapies? provenance
  2. Which questions should be asked of the specialist? action

Unproven

Unproven treatments.

Unproven

Unproven treatments.

  1. Does this offered treatment or supplement have regulatory approval and evidence? boundary
  2. What do regulators warn about? provenance
Support People and carers.

Support for all.

Organisations

Support organisations.

Organisations

Support.

  1. Which organisations support people with Alzheimer's disease and their carers here? provenance
  2. Which planning tools, such as advance care planning, exist? provenance

Research

Research participation.

Research

Research.

  1. Which trials and registries are recruiting, according to registries? provenance
  2. How can someone discuss participation with their team? action

What the second pass must settle

  • Should each form be a separate entry?
  • How should guidelines be linked?
  • How should support services be localised?